SEHK:548
SEHK:548Infrastructure

Shenzhen Expressway (SEHK:548) Net Profit Margin Drops Sharply, Challenging Stable-Growth Narrative

Shenzhen Expressway (SEHK:548) reported earnings that have declined by 10.8% per year over the past five years, and its net profit margin dropped to 13.2% from last year’s 24.6%. While revenue is forecast to grow at 5.5% per year, that is notably behind the Hong Kong market’s 8.7% average, and expected earnings growth of 8.02% still lags the wider market’s 12.4% pace. Margins have come under pressure, highlighting ongoing headwinds despite growth forecasts that suggest some upside potential...
SEHK:1952
SEHK:1952Biotechs

Everest Medicines (SEHK:1952): Valuation Insights Following Exclusive VIS-101 Ophthalmology Deal

Everest Medicines (SEHK:1952) has secured exclusive rights to develop and commercialize VIS-101, a promising bifunctional treatment for eye conditions like wet AMD, across Greater China and parts of Asia. This strategic move underscores the company’s ambitions in ophthalmology and signals potential growth ahead. See our latest analysis for Everest Medicines. Everest Medicines’ exclusive VIS-101 deal adds momentum to a year already marked by strong long-term performance. The company posted an...
SEHK:9926
SEHK:9926Biotechs

A Look at Akeso (SEHK:9926) Valuation Following Key Phase III HARMONi-6 Study Results

Akeso (SEHK:9926) was in the spotlight after recently published Phase III HARMONi-6 study results showed its bispecific antibody, ivonescimab, plus chemotherapy significantly improved progression-free survival in advanced squamous NSCLC compared to current treatments. See our latest analysis for Akeso. Akeso’s big clinical win comes after a year of remarkable momentum, with a year-to-date share price return of 93.5% and a 66.3% total shareholder return over the past twelve months. Excitement...
SEHK:939
SEHK:939Banks

China Construction Bank (SEHK:939) Net Margin Hits 54.7%, Reinforcing Value Narrative Despite Modest Growth

China Construction Bank (SEHK:939) has posted solid results with net profit margins reaching 54.7%, edging up from last year’s 54.2%. While earnings growth over the past year came in at 0.7%, below the five-year average of 4.6% per year, revenue is projected to rise at a robust 10.4% annually, beating the broader Hong Kong market’s 8.7% forecast. The earnings outlook for the next few years is more modest, with growth expected at 3.7% per year, trailing the Hong Kong average of 12.4%. See our...
SEHK:1171
SEHK:1171Oil and Gas

Yankuang Energy Group (SEHK:1171) Margin Drop Contradicts Resilience Narratives Despite Deep Valuation Discount

Yankuang Energy Group (SEHK:1171) reported a net profit margin of 7.7%, down from 13.2% last year. Over the past five years, annual earnings grew at a modest 2.7%, but the company saw negative earnings growth in the most recent period. While earnings are forecast to grow by 3.8% per year over the next three years, revenue is expected to decline by 0.8% per year. This leaves the projected growth rate notably slower than the Hong Kong market average of 12.4% per year. Investors should also note...